| Budget Amount *help |
¥45,110,000 (Direct Cost: ¥34,700,000、Indirect Cost: ¥10,410,000)
Fiscal Year 2020: ¥8,450,000 (Direct Cost: ¥6,500,000、Indirect Cost: ¥1,950,000)
Fiscal Year 2019: ¥9,230,000 (Direct Cost: ¥7,100,000、Indirect Cost: ¥2,130,000)
Fiscal Year 2018: ¥9,100,000 (Direct Cost: ¥7,000,000、Indirect Cost: ¥2,100,000)
Fiscal Year 2017: ¥10,270,000 (Direct Cost: ¥7,900,000、Indirect Cost: ¥2,370,000)
Fiscal Year 2016: ¥8,060,000 (Direct Cost: ¥6,200,000、Indirect Cost: ¥1,860,000)
|
|---|
| Outline of Final Research Achievements |
Using naive human pluripotent stem cells (PSCs), we established a differentiation model from pre-implantation trophectoderm to syncytiotrophoblast and extravillous trophoblast via post-implantation cytotrophoblast (CT). In addition, we established a culture method to induce hypoblast and produced bilaminar disk-like structures (bilaminiods) by co-culturing human pre-implantation epiblast and our naive PSC-derived hypoblast. Hypoblast generated the basement membrane and polarity of epiblast, the pro-amniotic cavity, and the anterior-posterior axis. Epiblast started to express primitive streak genes. These observations all suggest we could model the pre-implantation to post-implantation transition of the human embryo in vitro.
Finally, we succeeded in establishing new primed and naive marmoset PSCs, finding some signaling pathways were conserved in humans and marmosets. This result emphasizes the importance of using monkey embryo data when evaluating human PSCs.
|
